MRI / Gadolinium Practice Center: MRI Gadolinium Contrast Agent - ALERT Gadolinium Attorneys MRI Gadolinium Lawsuits Gadolinium Causing Medical Condition Nephrogenic Systemic Fibrosis What Is Nephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis? Gadolinium Lawyer We will work under a Contingency Fee Contract

Did you know that radiologists across the United States have been warned to avoid the use of contrast agents that contain gadolinium in patients with advanced renal disease if at all possible, according to the CDC. This Nationwide recommendation was part of a preliminary report on the largest cluster of nephrogenic systemic fibrosis (also known as nephrogenic fibrosing dermopathy), a rare condition characterized by thickening and hardening of the skin, often in the extremities, in St. Louis patients with underlying renal disease. Thus, unless there is no other option you should avoid using contrast agent - gadolinium - in patients with renal disease or other kidney issues or concerns. It is important to also note that more than 95% of the cases of nephrogenic fibrosing dermopathy have been associated with the use of this type of MRI Contrast Agent in patients with renal disease or other kidney issues.

The CDC report comes days after the European regulatory agency concluded that two of the agents -- gadodiamide (Omniscan) and gadoversetamide (OptiMark) -- are contraindicated in patients with advanced renal disease. The CDC report comes only weeks after the FDA warned of the possible link.

The mechanism of injury and a complete understanding of how Gadolinium-is causing and/or associated with nephrogenic fibrosing dermopathy is unknown. However, one hypothesis is that the gadolinium ions might dissociate from the chelate and result in a fibrotic reaction. In a recent  study, 35 patients with this condition were identified in St. Louis, and a matched case-control study showed that only gadolinium contrast agents were independently associated with the condition. In this study, exposure to the agents increased the risk of the condition nearly nine-fold, the researchers found. In a multivariate analysis, the odds ratio was 8.97 with a 95% confidence interval from 1.28 to 63.01. This research was prompted by a cluster of nephrogenic fibrosing dermopathy among dialysis patients in a St. Louis area hospital.  The investigation and review of the records found a total of 33 confirmed or suspected NSF/NFD cases between 2002 and 2006, of whom 28 had been treated at the hospital.

The findings were based on those confirmed cases, if both clinical findings, such as skin thickening or hardening, and the findings of a skin biopsy (punch or wedge) were consistent with the condition. A suspected case was one in which either clinical or biopsy findings but not both were consistent with the condition. The subsequent case-control study included 19 of the confirmed cases from the hospital, each matched with three unaffected patients who were treated in the same dialysis clinic or treatment center on the same day that a case was diagnosed.






























TRADEMARK NOTICE: Magnevist, Omniscan, OptiMARK, ProHance and Multihance are trademarks of Bayer Schering Pharma, GE Healthcare, Chalfont St. Giles and Bracco Diagnostics Inc. accordingly.

The Carabin & Shaw Law Firm, its' lawyers and this website is in no way affiliated with Bayer Schering Pharma, GE Healthcare, Chalfont St. Giles and Bracco Diagnostics Inc. The use of this mark is solely for informational and product identification purposes.